NGLFINE Q4 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹149 Cr
verified against source
Revenue YoY
57%
reported change
EBITDA
₹21.41 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
NGL Fine-Chem delivered a standout Q4 FY26 with 124.23 crore revenue (+57% YoY) and 48.13 crore PAT for FY26 (+128% YoY), marking the third consecutive quarter of operational improvement. The recovery is broad-based, driven by expanded product portfolio (45 APIs vs 20 three years ago), Latin America market penetration gains, and improved capacity utilization following Phase 1 commissioning. EBITDA margin of 14.35% expanded 769bps YoY but compressed sequentially due to geopolitical-driven freight and raw material cost pressures that could not be fully passed on under fixed-price contracts; partial price increases have been secured from Q1 FY27. Phase 2 Tarapur expansion faces a one-quarter delay to Q2 FY27 due to gas/labor shortages, with capex at 182.75 crore of 210 crore total. Management targets 15-18% EBITDA margin band and expects regulated market (EU) contribution to begin FY27 with US FDA audit timing remaining uncertain. Key risks include Chinese competition maintaining price discipline and potential delays in US FDA approvals for regulated market entry.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects to operate within the 15-18% EBITDA margin band going forward, supported by partial price increases already secured from Q1 FY27 and improving competitive dynamics as Chinese players begin raising prices.
- Phase 2 (5 clean rooms) plus Phase 1 combined expected to generate 350-400 crore incremental revenue at full utilization, to be achieved over 3-4 years.
- European market sales expected to begin in current financial year (FY27) as registrations come through; US market contribution anticipated primarily from FY28 onward.
- Company budget targets adding 9-10 new API products per year, with some quarters seeing accelerated additions (5 added in Q4).
Risks flagged
- Customer filings with US FDA will trigger audit requirements, but timing is entirely regulator-dependent and could extend into next year, delaying regulated market entry.
- Analyst directly asked for forex mark-to-market loss quantification; management deflected, stating they don't have the number available, leaving margin impact unclear.
- Chinese competitors did not raise prices during Q4 despite input cost increases, creating margin pressure that may persist in competitive segments, particularly in regulated market entry.
- Management acknowledged that 20-21% EBITDA margins seen historically are unlikely to return for 2-3 years due to significant Chinese and Indian capacity expansion creating structural oversupply.
Key quotes
- We have returned to a stronger growth trajectory with improving operational performance and better business momentum. FY26 has clearly been a year of recovery for the company. After three challenging years, we have returned to a stronger growth trajectory.
- We would like to maintain the 15 to 18% level which we are fairly close to at the current level. We have been partially successful in passing on price increase and China has started raising prices now which is a big relief to us.
- I would be a little cautious in not giving you numbers on this because the registrations need to go through for all the products, the regulator needs to come in, inspect and approve the facility. Let us for a couple of more quarters before we start committing to it.
Research modules